One Time Injection of Bacteria to Treat Solid Tumors That Have Not Responded to Standard Therapy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE1

Total Enrollment

2 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-07-31

Study Completion Date

2008-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will include a one time intravenous (IV) infusion of Clostridium novyi-NT (C. novyi-NT) spores to treat solid tumors which have not responded to standard therapy.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety Study of Clostridium Novyi-NT Spores to Treat Patients With Solid Tumors That Have Not Responded to Standard Therapies

NCT01118819

Solid Tumor Malignancies

TERMINATED PHASE1

Safety Study of Intratumoral Injection of Clostridium Novyi-NT Spores to Treat Patients With Solid Tumors That Have Not Responded to Standard Therapies

NCT01924689

Solid Tumor Malignancies

COMPLETED PHASE1

A Phase 1 Study Evaluating CB-5083 in Subjects With Advanced Solid Tumors

NCT02243917

Advanced Solid Tumors

TERMINATED PHASE1

A JZP341 Study in Adult Participants With Advanced or Metastatic Solid Tumors

NCT05631327

Advanced Solid Tumor Metastatic Solid Tumor

TERMINATED PHASE1

Ph. 1, Evaluation of Safety, Tolerability, PK, Anti-tumor Activity of STP707 IV in Subjects With Solid Tumors

NCT05037149

Solid Tumor

ACTIVE_NOT_RECRUITING PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Investigators at the SKCCC have developed a bacterial strain (C. novyi-NT) that can infect tumors and destroy them, but does not grow in normal tissues. In animal experiments, a single intravenous injection of these bacteria can cause dramatic regression of many tumors, and the tumors do not recur in approximately (\~) 30% of the animals.

This is a phase I dose escalation study using a single dose of Clostridium novyi-NT spores in patients with treatment-refractory solid tumor malignancies. The overall objective of this study is to determine the safety and document any preliminary evidence of anti-tumor activity in this patient population.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Tumors

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Treatment arm

Group Type EXPERIMENTAL

Clostridium novyi-NT spores

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Clostridium novyi-NT spores

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Histologically or cytologically proven solid tumor malignancy as proven by referral CT scan of the chest, abdomen and pelvis.
2. Patients must be refractory to standard chemotherapy or for whom no standard treatment exists. At least four weeks must have elapsed since completion of any prior chemotherapy.
3. Patients must have measurable disease; defined as at least one lesion whose longest diameter can be accurately measured as \>2 cm.
4. ECOG performance status of 0 or 1.
5. Prior locoregional therapy, including cryotherapy, radiofrequency ablation, or regional chemotherapy is allowed if at least 6 weeks have elapsed.
6. Prior radiation therapy is allowed. At least 6 weeks must have elapsed since the completion of radiation therapy and the patient must have recovered from side effects.
7. Prior systemic radionuclide therapy is allowed. At least 4 weeks must have elapsed since completion of the therapy.
8. Prior surgery is allowed. At least 6 weeks must have elapsed since the completion of major surgery and the patient must be fully recovered from this surgery and any attendant postsurgical complications.
9. Patients must be 18 years of age or older
10. Patients of childbearing potential must use adequate birth control measures (e.g., abstinence, barrier method with spermicide; or use by partner of oral contraceptives, intrauterine device, implantable or injectable contraceptives \[i.e., Norplant or Depo-Provera\] or surgical sterilization) for the duration of the study and should continue such precautions for 12 months after receiving treatment.
11. Screening physical exam must be obtained less than 7 days prior to treatment and the results must meet the following criteria:

1. Temperature range: \< 38.0 and greater and \>36.0
2. Respiratory rate: 10-20 breaths per minute
3. Heart rate: 50 - 85 beats per minute
4. Blood pressure: Systolic blood pressure greater than 90 mm Hg and less than 155 mm Hg
5. % oxygen saturation by pulse oximetry: \>93%
12. Screening laboratory tests will be obtained less than 7 days prior to treatment and the results must meet the following criteria:

1. WBC \> 3500/ mm3 and /or ANC \> 1500/ mm3, and Platelet count 100,000/ mm3.
2. Serum creatinine \< 1.5X upper limit of normal (ULN).
3. AST or ALT \< 2.5X ULN, Alkaline phosphatase \< 2.5X ULN, and Bilirubin \< 1.5X ULN.
4. INR \< 1.3
5. Hemoglobin \> 10.0 g/dL
13. Negative serum pregnancy test for females of childbearing potential.
14. The patient must be capable of giving informed consent and the consent must be obtained prior to any other screening procedures that are not considered standard procedures in this patient population.
15. A baseline transthoracic echocardiogram demonstrating a left ventricular ejection fraction (LVEF) greater than 50% and no significant valvular disease (Subjects with trace or mild valvular stenosis or regurgitation will be permitted to enroll in the study).
16. Patient is able to stay within 45 minutes driving time of Johns Hopkins Hospital for 28 days following spore injection and the 7 day in-patient hospitalization period.
17. Patient is able to stay within 45 minutes driving time of Johns Hopkins Hospital for at least 35 days after recovery from all adverse events.

Exclusion Criteria

1. Weight \> 135 kg
2. Chronic renal failure requiring hemodialysis or peritoneal dialysis
3. Patients with renal cysts.
4. Tumor lesion that is not accessible to percutaneous drainage.
5. Any single contiguous lesion greater than \> 12.5 cm (largest diameter).
6. The sum of the largest cross-sectional diameters from any number of non-contiguous lesions \> 2 cm cannot be \> 25 cm.
7. Use of any investigational drug within 30 days prior to screening or within 5 half-lives of the investigational agent, whichever is longer.
8. Any documented evidence of primary brain malignancy or brain metastases
9. Patients with any clinically significant ascites or portosystemic hypertension, chronic jaundice or cirrhosis.
10. Patients with indwelling intrahepatic arterial pumps
11. Patients with prosthetic joints, prosthetic valves, pacemakers or any other implanted foreign materials. (non-CNS surgical clips or staples are excluded)
12. Patients with any clinically significant pleural effusions
13. Patients with any evidence of hemodynamic compromise from a pericardial effusion, circumferential pericardial effusion, or any effusion greater than 1.0 cm at any location around the heart.
14. Documented cirrhosis of the liver by clinical scenarios encompassing radiographic,clinical and laboratory results
15. Ongoing treatment with any immunosuppressive agent(s)
16. Any evidence of serious infections (such as pneumonia or pyelonephritis) or history of chronic or recurrent infectious disease in the previous 3 months.

Less serious infections (such as acute upper respiratory tract infection(colds)or simple urinary tract infection) can be included upon the discretion of the investigator.
17. Patients with opportunistic infections, including but not limited to evidence of active cytomegalovirus, Tuberculosis, active Pneumocystis carinii, Aspergillosis,histoplasmosis, or atypical mycobacterium infection, within the previous 6 months.
18. Documented HIV infection.
19. Active or chronic Hepatitis B or Hepatitis C.
20. Presence of a transplanted solid organ (with the exception of a corneal transplant \> 3 months prior to screening).
21. History of an autoimmune disorder (eg, systemic lupus, pemphigus vulgaris,myasthenia gravis) ), requiring medication.
22. History of Diabetes Mellitus (type I or II)
23. History of rheumatic fever, endocarditis, or greater than mild valvular disease.
24. Patients who depend upon COX II inhibitors or NSAIDS
25. History of ongoing and active arterial vasculopathy (i.e. coronary artery disease, vasculitis, diabetic vasculopathy \[i.e. retinopathy, nephropathy, etc.\]) or evidence of end organ damage (visual loss, azotemia, and cutaneous ulcerations).
26. History of an ischemic insult in the previous 12 months (myocardial infarction, cerebra vascular accident, ischemic tissue from injury or peripheral vascular disease)
27. History of venous or lymphatic stasis resulting in venous stasis ulcers or greater than 2+ edema or lymphedema.
28. History of a significant medical illness deemed by the principal investigator or sub-investigators as unsuitable for the trial - for example:

1. Symptomatic congestive heart failure
2. Psychiatric Illness/Social Situation that may make study dangerous
3. Unstable angina pectoris
29. History of a splenectomy
30. Patients with a documented Penicillin or Metronidazole allergy
31. Patients with a documented allergy to radiology contrast dye.
32. Patient with active diverticulitis
33. Patient with active dental abscesses
34. Patients with inflammatory bowel disease (IBD)
35. Women who are pregnant, lactating or breast feeding
36. Patients with angiosarcoma
37. Patients with history of a positive PPD, past TB infection or past atypical mycobacterium infection.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No